Literature DB >> 31818808

Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease.

Corrado Campochiaro1,2, Giulio Cavalli3,2, Nicola Farina3,2, Alessandro Tomelleri3,2, Giacomo De Luca3,2, Lorenzo Dagna3,2.   

Abstract

Entities:  

Keywords:  autoimmunity; inflammation; treatment

Mesh：

Substances：

Year:  2019        PMID： 31818808     DOI： 10.1136/annrheumdis-2019-216610

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  4 in total

Review 1.  Erdheim-Chester disease: a rapidly evolving disease model.

Authors:  Francesco Pegoraro; Matthias Papo; Valerio Maniscalco; Frédéric Charlotte; Julien Haroche; Augusto Vaglio
Journal:  Leukemia       Date:  2020-06-26       Impact factor: 11.528

Review 2.  Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies.

Authors:  Arianna Ferlito; Corrado Campochiaro; Alessandro Tomelleri; Lorenzo Dagna; Giacomo De Luca
Journal:  J Scleroderma Relat Disord       Date:  2022-03-24

Review 3.  Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic.

Authors:  Giulio Cavalli; Nicola Farina; Corrado Campochiaro; Giacomo De Luca; Emanuel Della-Torre; Alessandro Tomelleri; Lorenzo Dagna
Journal:  Front Pharmacol       Date:  2020-12-18       Impact factor: 5.988

4.  Cardiac electrical instability in Erdheim-Chester disease: a case report.

Authors:  Andrea Urbani; Filippo Pensotti; Diego Castini; Silvia Magnani; Pasquale Simone Simeoli; Corrado Campochiaro; Lorenzo Dagna; Alberto M Cappelletti; Carlo Sponzilli; Marco Guazzi
Journal:  Oxf Med Case Reports       Date:  2022-07-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.